Chiltern has established two new offices and launched operations in Australia and Singapore – with Singapore acting as the hub for its operations in Southeast Asia. This builds upon Chiltern’s operation in India.
Chiltern is also in the process of forming a company and establishing operations in China. Chiltern’s Asia Pacific operations will be led by Umakanta Sahoo, Executive Director, Asia Pacific. Commenting on the growth, “Chiltern’s expansion will provide a platform from which global pharmaceutical and biotech Sponsors can expand their geographic reach and enhance patient recruitment in the Asia Pacific region,” stated Dr. Sahoo.
Glenn Kerkhof, Chiltern CEO, stated, “Asia Pacific is one of the foremost emerging markets in our industry. With the current expansion of pharmaceutical R & D needs into the Asia Pacific region, Chiltern is positioned to meet the needs this growth entails. We are very pleased to provide our clients with access to this market.”
Chiltern is currently recruiting clinical staff and plans to grow its workforce in the Asia Pacific region to 70 by the end of 2010.